

Epstein-Barr virus (EBV) is a common virus that spreads through saliva and causes infectious mononucleosis, also known as mono. Most individuals are exposed to EBV at some point in their lives, and while many have mild or no symptoms, some experience fatigue, sore throat, fever, and swollen lymph nodes.
The EBV IgM antibody to Viral Capsid Antigen test measures the levels of IgM antibodies in the blood, which appear early during infection. A positive result usually means a recent or active EBV infection. This test is particularly useful when someone presents with symptoms such as extreme tiredness, fever, sore throat, or enlarged spleen, and EBV is suspected.
Doctors may recommend this test if there are symptoms of mono, unexplained lymph node enlargement, or other signs of a viral illness. It is often used along with other EBV antibody tests for a comprehensive diagnosis.
No special preparation is required for the EBV IgM antibody to Viral Capsid Antigen test. However, a brief clinical history is preferred during sample collection. Inform the doctor about all the medications and supplements currently being taken, as some of them may affect the test results, potentially requiring dosage adjustments or temporary discontinuation before the test.
Test result ranges are approximate and may differ slightly between labs depending on the methodology and laboratory guidelines. Do not self-medicate, and always consult a doctor to understand the test results correctly.
Please note: This is an outsourced test. The sample is collected by TATA 1MG and processed at a NABL accredited partnered lab.
The EBV IgM antibody to Viral Capsid Antigen is a blood test that measures IgM antibodies against the viral capsid antigen (VCA) of the Epstein-Barr virus. The presence of these antibodies indicates a recent or current infection.
The EBV IgM antibody to Viral Capsid Antigen test is done:
- To detect early or recent EBV infection.
- To differentiate between present and past EBV infection.
- To support the diagnosis of infectious mononucleosis.
- To evaluate immunity to EBV after vaccination.
- To assess the risk of complications associated with EBV infection.
- To screen for increased susceptibility to future EBV infections.
- Clinical history is preferred.































